|
|
||||||||||||||||||||||||||||||||||||||||||||
By The Online Investor Staff, updated Tue., Jan. 26, 6:25 AM
|
|||||||||||||||||||||||||||||||||||||||||||||
Secondary Stock Offerings| This Slide: #13 of 25 |
Slide #13. Chimerix, Inc. — Secondary Offering
Company:
Chimerix, Inc. (NASDAQ:CMRX)
Date announced:
1/19/2021
Secondary Offering Details:
Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today that it intends to offer and sell, subject to market and other conditions, up to $75,000,000 of shares of its common stock in an underwritten public offering. In addition, Chimerix expects to grant the underwriters a 30-day option to purchase up to an additional $11,250,000 of shares of common stock. All of the shares to be sold in the offering are to be sold by Chimerix. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Chimerix is a biopharmaceutical company focused on developing medicines for patients living with cancer and other serious diseases. Co.'s two clinical-stage development programs are dociparstat sodium, a potential glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of several key proteins implicated in the retention and viability of AML blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir, an oral antiviral in development as a medical countermeasure for the treatment of smallpox.
CMRX SEC Filing Email Alerts Service
Open the CMRX Page at The Online Investor »
|
|||||||||||||||||||||
Open the CMRX Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
|
Buy (3.00 out of 4) 34th percentile
(ranked lower than approx. 66% of all stocks covered)
Analysts' Target Price: CMRX Stock Forecast Based on Zacks ABR data; powered by Xignite |
Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.